Uses Of Dc-sign And Dc-signr For Inhibiting Hepatitis C Virus Infection

Full-text?

The full document isn't yet available to us from the patent office.

Abstract

This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. This infection provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGNR protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. Compounds of the present invention inhibit HCV infection of cells susceptible to HCV infection. The compounds of the present invention preferably have specificity for preventing or inhibiting infection by HCV and do not inhibit infection by other viruses, such as HIV, that may utilize DC-SIGN or DC-SIGNR for infection. Moreover the compounds of the present invention preferably do not interfere or inhibit members of the immunoglobulin superfamily, in particular, the compounds do not interfere with ICAM-2 or ICAM-3 or with ICAM-2-ilke, or ICAM-3-like molecules.


Claims

Information currently unavailable.

IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jul 23, 2008
  • Application: Jun 26, 2002
    EP EP 08000261 A
  • Priority: Jun 26, 2002
    EP EP 02759107 A
  • Priority: Jun 26, 2001
    US US 89189401 A

Sign in to the Lens

Feedback